MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

被引：33

作者：

Peters, S. ^{[1
]}

Antonia, S. ^{[2
]}

Goldberg, S. B. ^{[3
]}

Heymach, J. V. ^{[4
]}

Kim, E. S. ^{[5
]}

Nakagawa, K. ^{[6
]}

Papadimitrakopoulou, V. ^{[4
]}

Mukhopadhyay, P. ^{[7
]}

McIntosh, S. ^{[8
]}

Rizvi, N. A. ^{[9
]}

机构：

[1] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA

[3] Yale Univ, Dept Med, Yale Canc Ctr, New Haven, CT 06520 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[5] Carolinas HealthCare Syst, Levine Canc Inst, Dept Solid Tumor Oncol, Charlotte, NC USA

[6] Kinki Univ, Sch Med, Dept Med Oncol, Osaka, Japan

[7] AstraZeneca, Global Med Dev Biometr & Informat Sci, Gaithersburg, MD USA

[8] AstraZeneca, Global Med Dev, Alderley Pk, Macclesfield, Cheshire, England

[9] Columbia Univ Hosp, Dept Med, New York, NY USA

来源：

关键词：

D O I：

10.1016/S1556-0864(16)30300-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

191TiP

引用

页码：S139 / S140

页数：2